LLY

918.04

-1.5%↓

JNJ

237.29

-1.12%↓

ABBV

209.67

-5.52%↓

NVS

150.84

-2.63%↓

AZN

189.69

-1.13%↓

LLY

918.04

-1.5%↓

JNJ

237.29

-1.12%↓

ABBV

209.67

-5.52%↓

NVS

150.84

-2.63%↓

AZN

189.69

-1.13%↓

LLY

918.04

-1.5%↓

JNJ

237.29

-1.12%↓

ABBV

209.67

-5.52%↓

NVS

150.84

-2.63%↓

AZN

189.69

-1.13%↓

LLY

918.04

-1.5%↓

JNJ

237.29

-1.12%↓

ABBV

209.67

-5.52%↓

NVS

150.84

-2.63%↓

AZN

189.69

-1.13%↓

LLY

918.04

-1.5%↓

JNJ

237.29

-1.12%↓

ABBV

209.67

-5.52%↓

NVS

150.84

-2.63%↓

AZN

189.69

-1.13%↓

Search

Ascendis Pharma A-S ADR

Deschisă

SectorSănătate

230.22 0.1

Rezumat

Modificarea prețului

24h

Curent

Minim

224.38

Maxim

230.37

Indicatori cheie

By Trading Economics

Venit

28M

-33M

Vânzări

32M

245M

Marjă de profit

-13.56

Angajați

1,189

EBITDA

68M

15M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+26.93% upside

Dividende

By Dow Jones

Următoarele câștiguri

30 apr. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

618M

14B

Deschiderea anterioară

230.12

Închiderea anterioară

230.22

Sentimentul știrilor

By Acuity

54%

46%

280 / 351 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Ascendis Pharma A-S ADR Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

17 mar. 2026, 22:42 UTC

Câștiguri

Prudential PLC 2025 Adjusted Operating Profit Rises

17 mar. 2026, 21:40 UTC

Câștiguri

Alimentation Couche-Tard Records Higher Profit, Revenue in 3Q

17 mar. 2026, 23:56 UTC

Market Talk

BHP's Next CEO Likely to Build On Existing Strategic Direction -- Market Talk

17 mar. 2026, 23:46 UTC

Market Talk

Nikkei May Rise After Recent Selloffs -- Market Talk

17 mar. 2026, 23:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 mar. 2026, 23:42 UTC

Market Talk

RBA's Return to Policy Tightening Will Work -- Market Talk

17 mar. 2026, 23:38 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments Before FOMC Decision -- Market Talk

17 mar. 2026, 23:24 UTC

Market Talk

Global Energy Roundup: Market Talk

17 mar. 2026, 23:24 UTC

Market Talk

New Woodside CEO Seen as Low-Risk Appointment -- Market Talk

17 mar. 2026, 22:22 UTC

Market Talk

BHP Hands Reins to Growth-Focused Executive -- Market Talk

17 mar. 2026, 22:20 UTC

Câștiguri

Prudential PLC 2025 New Business Profit $2.78B Vs. $2.46B >2378.HK

17 mar. 2026, 22:20 UTC

Câștiguri

Prudential PLC 2025 Adj Operating Profit $3.31B Vs. $3.13B >2378.HK

17 mar. 2026, 22:07 UTC

Câștiguri

Nvidia Says It Is Restarting Production of AI Chips for Sale in China -- WSJ

17 mar. 2026, 22:05 UTC

Câștiguri

ZTO Express (Cayman): Frank Zhen Wei to Resign From Board

17 mar. 2026, 22:04 UTC

Câștiguri

ZTO Express (Cayman): Board Approves Repurchase of Up to $1.5B of Shares Over Next 24 Months >ZTO

17 mar. 2026, 22:03 UTC

Câștiguri

ZTO Express (Cayman) Raises Semiannual Dividend to 39c Vs. 30c >ZTO

17 mar. 2026, 22:01 UTC

Câștiguri

ZTO Express (Cayman) 4Q Adj EPS 47c >ZTO

17 mar. 2026, 22:01 UTC

Câștiguri

ZTO Express (Cayman) 4Q Rev $2.08B >ZTO

17 mar. 2026, 22:01 UTC

Câștiguri

ZTO Express (Cayman) 4Q EPS 47c >ZTO

17 mar. 2026, 21:26 UTC

Câștiguri

Oklo Stock Wavers After Earnings, but the Nuclear Start-Up Has Good News -- Barrons.com

17 mar. 2026, 21:09 UTC

Câștiguri

Couche-Tard: 12 Company-Operated Stores Acquired During 3Q

17 mar. 2026, 21:08 UTC

Câștiguri

Couche-Tard 3Q Consolidated Same-Store Merchandise Revenue Up 2% >ATD.T

17 mar. 2026, 21:08 UTC

Câștiguri

Couche-Tard 3Q Adj EPS 81c >ATD.T

17 mar. 2026, 21:07 UTC

Câștiguri

Couche-Tard 3Q EPS 82c >ATD.T

17 mar. 2026, 21:06 UTC

Câștiguri

Couche-Tard 3Q Rev $21.8B >ATD.T

17 mar. 2026, 21:05 UTC

Câștiguri

Couche-Tard 3Q Adj EPS 81c >ATD.T

17 mar. 2026, 21:05 UTC

Câștiguri

Couche-Tard 3Q Rev $21.8B >ATD.T

17 mar. 2026, 21:05 UTC

Câștiguri

Couche-Tard 3Q EPS 82c >ATD.T

17 mar. 2026, 21:05 UTC

Câștiguri

Couche-Tard 3Q Net $757.2M >ATD.T

17 mar. 2026, 20:50 UTC

Market Talk
Evenimente importante

Energy & Utilities Roundup: Market Talk

Comparație

Modificare preț

Ascendis Pharma A-S ADR Așteptări

Obiectiv de preț

By TipRanks

26.93% sus

Prognoză pe 12 luni

Medie 293.23 USD  26.93%

Maxim 342 USD

Minim 255 USD

În baza a 13 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAscendis Pharma A-S ADR - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

13 ratings

13

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

157.66 / 167.29Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Bullish Evidence

Termen lung

Strong Bullish Evidence

Sentiment

By Acuity

280 / 351 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
help-icon Live chat